February 25, 2025: Francis Medical completes enrollment in the company's VAPOR 2 Pivotal Study for Vanquish Prostate Cancer Treatment
January 7, 2025: Francis Medical raises record $80M in Series C to fund its VAPOR 2 study and U.S. launch of Vanquish, its proprietary prostate cancer treatment.
In a revealing interview with Citeline Commercial's Medtech Insight, CEO Mike Kujak discusses how Francis Medical's Vanquish system is set to redefine prostate cancer treatment.
Francis Medical CEO Mike Kujak shares the highs and lows of being the CEO of a medtech startup and provides a window into the journey at Francis Medical.
Vanquish Water Vapor Ablation System featured in the October 2023 Minnesota Physician Journal
August 1, 2023: Francis Medical today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its Vanquish minimally invasive water vapor ablation therapy.
July 19, 2023: Francis Medical today announced the first patient has been treated in the company’s VAPOR 2 pivotal clinical study evaluating the safety and efficacy of its Vanquish minimally invasive water vapor ablation therapy for managing prostate cancer.
January 26, 2023: Francis Medical has appointed to its board of directors Andrew Cleeland, a leader with extensive experience in healthcare innovation and the development and deployment of new medical technologies.
CAUTION: Investigational device. Limited by United States law to investigational use.
7351 Kirkwood Lane N., Suite 130, Maple Grove, MN 55369
Phone: 763-951-0370
Email: info@francismedical.com
Developing novel, disruptive therapeutic solutions to treat prostate, kidney and bladder cancer.
© Copyright Francis Medical, Inc. 2024 | ALL RIGHTS RESERVED | 4206-001_02